MCID: OBS002
MIFTS: 68

Obsessive-Compulsive Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Obsessive-Compulsive Disorder

MalaCards integrated aliases for Obsessive-Compulsive Disorder:

Name: Obsessive-Compulsive Disorder 53 12 36 28 51 40 41 14 69 59
Obsessive-Compulsive Disorder, Protection Against 53 13
Ocd 53 72
Obsessive-Compulsive Disorder, Susceptibility to 53
Obsessive Compulsive Disorder 12
Obsessive Compulsive Behavior 69
Obsessive-Compulsive Behavior 28
Anancastic Neurosis 12

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant form


HPO:

31
obsessive-compulsive disorder:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 164230
Disease Ontology 12 DOID:10933
ICD10 32 F42
ICD9CM 34 300.3
MeSH 41 D009771
NCIt 46 C88411
MedGen 39 C0028768
KEGG 36 H01450
SNOMED-CT via HPO 65 263681008 12479006

Summaries for Obsessive-Compulsive Disorder

MedlinePlus : 40 Obsessive-compulsive disorder (OCD) is a type of anxiety disorder. If you have OCD, you have frequent, upsetting thoughts called obsessions. To try to control the thoughts, you feel an overwhelming urge to repeat certain rituals or behaviors. These are called compulsions. Examples of obsessions are a fear of germs or a fear of being hurt. Compulsions include washing your hands, counting, checking on things, or cleaning. With OCD, the thoughts and rituals cause distress and get in the way of your daily life. Researchers think brain circuits may not work properly in people who have OCD. It tends to run in families. The symptoms often begin in children or teens. Treatments include therapy, medicines, or both. One type of therapy, cognitive behavioral therapy, is useful for treating OCD. NIH: National Institute of Mental Health

MalaCards based summary : Obsessive-Compulsive Disorder, also known as obsessive-compulsive disorder, protection against, is related to trichotillomania and gilles de la tourette syndrome, and has symptoms including obsessive-compulsive behavior, pseudobulbar behavioral symptoms and restlessness. An important gene associated with Obsessive-Compulsive Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Serotonergic synapse and Dopaminergic synapse. The drugs Topiramate and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are Decreased viability and Decreased viability

OMIM : 53 Obsessive-compulsive disorder (OCD) is characterized by recurring obsessions and/or compulsions and has been estimated to affect nearly 5 million people in the United States (Karno et al., 1988). Evidence for a strong genetic component in OCD comes from twin studies, family genetics studies, and segregation analyses, as reviewed by Alsobrook et al. (2002). Zhang et al. (2002) suggested that hoarding is likely to be an evolutionarily conserved trait that, in times of adversity, was associated with increased survival and reproductive fitness. However, extreme forms of this trait are associated with marked disability and poor response to treatment (Black et al., 1998; Mataix-Cols et al., 1999). (164230)

Disease Ontology : 12 An anxiety disorder that involves unwanted and repeated thoughts, feelings, ideas, sensations (obsessions), or behaviors that make them feel driven to do something (compulsions).

PubMed Health : 59
About obsessive-compulsive disorder: We all know the worrying feeling that we have forgotten to do something, like turning off the oven or locking the door. And it might be a good idea to double-check if you aren't absolutely sure. But some people are so worried about forgetting to do something that they feel the urge to check over and over again. Compulsive urges like this may gradually come to dominate their whole life. There are different types of obsessive-compulsive disorder (OCD). Some people are so afraid of germs that they constantly wash their hands. Others can't stop counting things, cleaning their surroundings or obsessing over the same repetitive thoughts. Regardless of the kind of ritual they may have developed, people who have OCD just can't stop doing these things.

Wikipedia : 72 Obsessive–compulsive disorder (OCD) is a mental disorder where people feel the need to check things... more...

Related Diseases for Obsessive-Compulsive Disorder

Diseases related to Obsessive-Compulsive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 trichotillomania 32.3 DLGAP3 SLITRK1
2 gilles de la tourette syndrome 32.0 BDNF COMT DRD2 DRD4 HTR3A SGCE
3 autism spectrum disorder 31.5 BDNF COMT DRD2 DRD4 HTR2A MAOA
4 bulimia nervosa 2 31.4 BDNF COMT HTR2A SLC6A4
5 agoraphobia 31.3 HTR1A MAOA SLC6A4
6 alexithymia 31.1 COMT DRD2 HTR1A SLC6A4
7 social phobia 31.1 DRD2 HTR3A MAOA SLC6A4
8 dysthymic disorder 31.0 HTR2A MAOA SLC6A4
9 pathological gambling 30.9 DRD2 DRD4 HTR2A MAOA SLC6A3 SLC6A4
10 anxiety 30.9 BDNF COMT HTR1A HTR2A HTR2C HTR3A
11 tic disorder 30.8 DRD2 DRD4 HTR2A SLC6A3 SLITRK1 TPH2
12 brain injury 30.8 BDNF COMT DRD2
13 asperger syndrome 30.8 OXT SGCE SLC6A4
14 kleptomania 30.7 HTR1A MAOA SLC6A4 SLITRK1
15 eating disorder 30.7 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
16 traumatic brain injury 30.6 BDNF COMT DRD2
17 phobia, specific 30.6 COMT MAOA
18 schizoaffective disorder 30.6 BDNF COMT DRD2 HTR2A SLC1A1 SLC6A4
19 drug dependence 30.6 BDNF DRD2 SLC6A4
20 separation anxiety disorder 30.6 DRD4 OXT SLC6A3
21 pervasive developmental disorder 30.5 BDNF OXT SLC6A4
22 bipolar i disorder 30.5 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
23 post-traumatic stress disorder 30.4 BDNF COMT DRD2 HTR2A MAOA SLC6A4
24 temporal lobe epilepsy 30.4 BDNF HTR1A SLC1A1
25 generalized anxiety disorder 30.4 BDNF DRD2 HTR1A HTR2A HTR3A MAOA
26 impulse control disorder 30.3 DLGAP3 DRD2 DRD4 SLITRK1
27 bulimia nervosa 1 30.2 BDNF COMT HTR1B HTR2A HTR3A MAOA
28 paranoid schizophrenia 30.1 BDNF COMT HTR2A MAOA SLC6A4 TPH2
29 narcolepsy 30.1 COMT DRD2 HTR2A SLC6A3 TPH1
30 serotonin syndrome 30.0 HTR1A HTR2A HTR3A MAOA OXT SLC6A4
31 early-onset schizophrenia 30.0 BDNF COMT DRD2 DRD4 HTR2A HTR3A
32 panic disorder 29.9 BDNF COMT HTR1A HTR2A HTR2C HTR3A
33 autism 29.8 BDNF COMT DRD2 DRD4 HTR1A HTR2A
34 personality disorder 29.4 BDNF COMT DRD2 DRD4 HTR1A HTR1B
35 mood disorder 29.1 BDNF COMT DRD2 DRD4 HTR1A HTR1B
36 bipolar disorder 28.9 BDNF COMT DRD2 DRD4 HTR1A HTR2A
37 schizophrenia 28.8 BDNF COMT DRD2 DRD4 HTR1A HTR1B
38 psychotic disorder 28.8 BDNF COMT DRD2 DRD4 HTR1A HTR2A
39 attention deficit-hyperactivity disorder 28.7 BDNF COMT DRD2 DRD4 HTR1A HTR1B
40 migraine with or without aura 1 28.5 COMT DRD2 DRD4 HTR1A HTR1B HTR2A
41 major depressive disorder 28.3 BDNF COMT DRD2 DRD4 HTR1A HTR1B
42 alcohol dependence 28.2 BDNF COMT DRD2 DRD4 HTR1A HTR1B
43 osteochondritis dissecans 11.8
44 pandas 11.5
45 intellectual developmental disorder with neuropsychiatric features 11.3
46 dystonia 11, myoclonic 11.2
47 dystonia, dopa-responsive 11.1
48 succinic semialdehyde dehydrogenase deficiency 11.1
49 chromosome 15q11.2 deletion syndrome 11.1
50 mental retardation, autosomal dominant 23 11.1

Comorbidity relations with Obsessive-Compulsive Disorder via Phenotypic Disease Network (PDN):


Anxiety Dependent Personality Disorder
Dysthymic Disorder Generalized Anxiety Disorder
Hypothyroidism Major Depressive Disorder
Obsessive-Compulsive Personality Disorder Schizophreniform Disorder

Graphical network of the top 20 diseases related to Obsessive-Compulsive Disorder:



Diseases related to Obsessive-Compulsive Disorder

Symptoms & Phenotypes for Obsessive-Compulsive Disorder

Symptoms via clinical synopsis from OMIM:

53
Neuro:
obsessive-compulsive disorder


Clinical features from OMIM:

164230

Human phenotypes related to Obsessive-Compulsive Disorder:

31
# Description HPO Frequency HPO Source Accession
1 obsessive-compulsive behavior 31 HP:0000722

UMLS symptoms related to Obsessive-Compulsive Disorder:


pseudobulbar behavioral symptoms, restlessness, personality changes, mental and behavioral signs and symptoms, psychiatric symptom, photophobia, sleep disturbances

GenomeRNAi Phenotypes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.1 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Obsessive-Compulsive Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.43 HTR2A HTR2C HTR3A MAOA OXT SGCE
2 homeostasis/metabolism MP:0005376 10.2 BDNF COMT DRD2 DRD4 HTR1A HTR2C
3 cardiovascular system MP:0005385 10.13 COMT DRD2 HTR1A HTR1B MAOA OXT
4 growth/size/body region MP:0005378 10.11 HTR3A OXT SLC6A3 SLC6A4 SLITRK1 TPH1
5 endocrine/exocrine gland MP:0005379 10.1 OXT SLC6A3 SLC6A4 SLITRK1 BDNF COMT
6 adipose tissue MP:0005375 10.02 DRD2 HTR1B HTR2C OXT SLC1A1 TPH1
7 integument MP:0010771 9.96 SLC6A3 SLC6A4 TPH1 TPH2 BDNF DLGAP3
8 nervous system MP:0003631 9.86 BDNF COMT DLGAP3 DRD2 DRD4 HTR1A
9 muscle MP:0005369 9.81 DRD2 HTR1B HTR2A HTR2C HTR3A SGCE
10 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Obsessive-Compulsive Disorder

PubMedHealth treatment related to Obsessive-Compulsive Disorder: 59

Although there's no “cure” for OCD, with good professional help the symptoms can be reduced to a tolerable level, enabling people with OCD to start leading normal lives again.People with OCD are usually advised to have psychological treatment. Cognitive behavioral therapy (CBT) in particular has been proven to be an effective treatment for OCD. In Germany, it is offered by behavioral therapists (in German: Verhaltenstherapeuten).Medication for depression (antidepressants) may be considered in addition to CBT, or if psychological treatment isn't an option (yet). Selective serotonin re-uptake inhibitors (SSRIs) are commonly used for this purpose.Apart from these treatments, self-help is an option, for example by talking to other people with OCD in a support group. Some people like to use books or websites to learn about their obsessive-compulsive behaviors and deal with them. Others may try to manage their OCD using relaxation techniques like meditation or autogenic training.

Drugs for Obsessive-Compulsive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 224)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
2
Citalopram Approved Phase 4,Phase 3,Phase 2 59729-33-8 2771
3
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 5324346 3404
4
Clomipramine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 303-49-1 2801
5
Cycloserine Approved Phase 4,Phase 3,Phase 2 68-41-7 6234 401
6
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
7
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
10
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
11
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
12
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
13
Haloperidol Approved Phase 4 52-86-8 3559
14
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
15
Methylphenidate Approved, Investigational Phase 4,Phase 2 20748-11-2, 113-45-1 4158
16
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
17
Ethanol Approved Phase 4,Phase 2 64-17-5 702
18
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
19
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
20
Propranolol Approved, Investigational Phase 4 525-66-6 4946
21
Maleic acid Experimental Phase 4,Phase 3 110-16-7 444266
22 Anticonvulsants Phase 4,Phase 3,Phase 2
23 Anti-Obesity Agents Phase 4,Phase 3
24 Neuroprotective Agents Phase 4,Phase 3,Phase 2
25 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1
28 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Cholinergic Agents Phase 4,Phase 3,Phase 2
31 Cholinergic Antagonists Phase 4,Phase 3,Phase 2
32 Muscarinic Antagonists Phase 4,Phase 3,Phase 2
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35 Parasympatholytics Phase 4,Phase 3,Phase 2
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
38
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
39 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
41 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2
42 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3
44 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
45 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Antidepressive Agents, Tricyclic Phase 4,Phase 3,Phase 2
47 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
48 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
49 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 379)

# Name Status NCT ID Phase Drugs
1 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Unknown status NCT00211744 Phase 4 topiramate
2 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
3 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
4 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
5 Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
6 Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00116532 Phase 4 Escitalopram
7 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00464698 Phase 4 Duloxetine
8 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
9 Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF) Completed NCT01135745 Phase 4
10 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
11 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
12 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
13 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
14 Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) Completed NCT00796497 Phase 4 ondansetron
15 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Completed NCT00723060 Phase 4 escitalopram
16 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
17 Augmentation in Tx-resistant OCD: an Open Label Trial Completed NCT00590642 Phase 4
18 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
19 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
20 Antidepressant Safety in Kids Study Completed NCT00395213 Phase 4 Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
21 Escitalopram in Schizophrenia in OCD- Open Label Study Completed NCT00456937 Phase 4 Escitalopram
22 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
23 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
24 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
25 Probiotic Treatment in Adult Obsessive-Compulsive Disorder Recruiting NCT02334644 Phase 4
26 Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD) Recruiting NCT00182520 Phase 4 Topiramate;placebo
27 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Recruiting NCT00994786 Phase 4 pregabalin;Placebo
28 Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. Recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
29 Brief Intervention for OCD Fears Recruiting NCT02790710 Phase 4 Propanolol;Placebo
30 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Recruiting NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
31 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
32 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
33 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Active, not recruiting NCT01339858 Phase 4 N-Acetyl Cysteine
34 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
35 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
36 Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
37 Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
38 Intravenous Immunoglobulin for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections) Unknown status NCT01281969 Phase 3 Gamunex Intravenous Immunoglobulin;Placebo
39 A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder Completed NCT01933919 Phase 3 Fluvoxamine maleate;Placebo
40 Comparison of DBS Targets in Obsessive-compulsive Disorder Completed NCT01807403 Phase 3
41 Study of Sequentially Applied Repetitive Transcranial Magnetic Stimulation in Obsessive- Compulsive Disorders Completed NCT00932204 Phase 3
42 Quetiapine Augmentation in Severe Obsessive Compulsive Disorder Completed NCT00254735 Phase 3 quetiapine fumarate;SSRI/Clomipramine
43 Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder Completed NCT00187928 Phase 3 Topiramate
44 A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder Completed NCT00369642 Phase 3
45 Treatment of Obsessive-Compulsive Disorder (OCD) in Children Completed NCT00000384 Phase 3 Sertraline
46 D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD) Completed NCT01411774 Phase 3 d-cycloserine;Pill placebo
47 Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD) Completed NCT00305500 Phase 3 escitalopram
48 Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder Completed NCT00533806 Phase 3
49 Treatment of Obsessive Compulsive Disorder in Children Completed NCT00074815 Phase 3 Serotonin reuptake inhibitors management
50 Family Based Treatment of Early Childhood Obsessive Compulsive Disorder Completed NCT00055068 Phase 3

Search NIH Clinical Center for Obsessive-Compulsive Disorder

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: obsessive-compulsive disorder

Genetic Tests for Obsessive-Compulsive Disorder

Genetic tests related to Obsessive-Compulsive Disorder:

# Genetic test Affiliating Genes
1 Obsessive-Compulsive Disorder 28 BDNF HTR2A SLC6A4
2 Obsessive-Compulsive Behavior 28

Anatomical Context for Obsessive-Compulsive Disorder

MalaCards organs/tissues related to Obsessive-Compulsive Disorder:

38
Brain, Cortex, Testes, Subthalamic Nucleus, Skin, Prefrontal Cortex, Cingulate Cortex

Publications for Obsessive-Compulsive Disorder

Articles related to Obsessive-Compulsive Disorder:

(show top 50) (show all 1130)
# Title Authors Year
1
Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder. ( 29394511 )
2018
2
Sertraline induced cervical dystonia in a patient of Obsessive Compulsive Disorder. ( 29447992 )
2018
3
Treatment-Refractory Obsessive-Compulsive Disorder in Adults: A Cost-Effectiveness Analysis of Treatment Strategies. ( 29419948 )
2018
4
The temporal relationship between premonitory urges and covert compulsions in patients with obsessive-compulsive disorder. ( 29407570 )
2018
5
The relationship between theory of mind and insight in obsessive-compulsive disorder. ( 29426262 )
2018
6
Altered Functional Connectivity of the Default Mode Network in Patients With Schizo-obsessive Comorbidity: A Comparison Between Schizophrenia and Obsessive-compulsive Disorder. ( 29365198 )
2018
7
A Case of Obsessive-Compulsive Disorder Comorbid with Miyoshi Myopathy. ( 29403136 )
2018
8
Assessing Acute Secondary Treatment Outcomes in Early-Onset Obsessive-Compulsive Disorder. ( 29435695 )
2018
9
Presidential Address: Are the Obsessive-Compulsive Related Disorders Related to Obsessive-Compulsive Disorder? A Critical Look at DSM-5's New Category. ( 29405915 )
2018
10
A Meta-Analysis of the Effectiveness of Different Cortical Targets Used in Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Obsessive-Compulsive Disorder (OCD). ( 29423665 )
2018
11
Intolerance of uncertainty in youth with obsessive-compulsive disorder and generalized anxiety disorder: A transdiagnostic construct with implications for phenomenology and treatment. ( 29426573 )
2018
12
Progress and challenges in deep brain stimulation for obsessive-compulsive disorder. ( 29406245 )
2018
13
Changing disgust through imagery rescripting and cognitive reappraisal in contamination-based obsessive-compulsive disorder. ( 29421371 )
2018
14
Multivariate resting-state functional connectivity predicts response to cognitive behavioral therapy in obsessive-compulsive disorder. ( 29440404 )
2018
15
Eveningness is associated with poor sleep quality and negative affect in obsessive-compulsive disorder. ( 29415552 )
2018
16
Cost-effectiveness of deep brain stimulation versus treatment as usual for obsessive-compulsive disorder. ( 28457837 )
2017
17
Pedophilia-Themed Obsessive-Compulsive Disorder: Assessment, Differential Diagnosis, and Treatment with Exposure and Response Prevention. ( 28822003 )
2017
18
Parental age and the risk of obsessive compulsive disorder and Tourette syndrome / chronic tic disorder in a nationwide population-based sample. ( 28738196 )
2017
19
Shared and disorder-specific task-positive and default mode network dysfunctions during sustained attention in paediatric Attention-Deficit/Hyperactivity Disorder and obsessive/compulsive disorder. ( 28529874 )
2017
20
Mechanisms of cognitive-behavioral therapy for obsessive-compulsive disorder involve robust and extensive increases in brain network connectivity. ( 28872637 )
2017
21
Cognitive control networks in OCD: A resting-state connectivity study in unmedicated patients with obsessive-compulsive disorder and their unaffected relatives. ( 28918693 )
2017
22
Neurocognitive Function in Pediatric Obsessive-Compulsive Disorder. ( 28090807 )
2017
23
Overvalued ideation in adolescents with obsessive-compulsive disorder. ( 28528243 )
2017
24
L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. ( 28485008 )
2017
25
Effect of Religious Cognitive Behavioral Therapy on Religious Obsessive-compulsive Disorder (3 and 6 months Follow-up). ( 29387669 )
2017
26
Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis. ( 28477500 )
2017
27
Vitamin B12, folic acid, homocysteine and vitamin D levels in children and adolescents with obsessive compulsive disorder. ( 28477545 )
2017
28
The Nepean Belief Scale: preliminary reliability and validity in obsessive-compulsive disorder. ( 28885070 )
2017
29
Planning functioning and impulsiveness in obsessive-compulsive disorder. ( 28466133 )
2017
30
Executive Functions of Obsessive Compulsive Disorder and Panic Disorder Patients in Comparison to Healty Controls. ( 29321703 )
2017
31
Prevalence and correlates of obsessive-compulsive disorder and subthreshold obsessive-compulsive disorder among college students in Kerala, India. ( 28529361 )
2017
32
Metabolic and Cardiovascular Complications in Obsessive-Compulsive Disorder: A Total Population, Sibling Comparison Study With Long-Term Follow-up. ( 29395042 )
2017
33
Embracing Uncertainty as a First-Year Therapist Treating a Patient Who Has Obsessive-Compulsive Disorder. ( 28457206 )
2017
34
Choreatic side-effects of deep brain stimulation of the anteromedial subthalamic nucleus for treatment-resistant obsessive-compulsive disorder: a case report. ( 28532905 )
2017
35
Volitional saccade performance in a large sample of patients with obsessive-compulsive disorder and unaffected first-degree relatives. ( 28481032 )
2017
36
Increased Loss Aversion in Unmedicated Patients with Obsessive-Compulsive Disorder. ( 29379449 )
2017
37
Compulsive skin-picking behavior after deep brain stimulation in a patient with refractory obsessive-compulsive disorder: A case report. ( 28885367 )
2017
38
Early Onset Schizophrenia Associated With Obsessive-Compulsive Disorder: Clinical Features and Correlates. ( 28976410 )
2017
39
Rare Synaptogenesis-Impairing Mutations in SLITRK5 Are Associated with Obsessive Compulsive Disorder. ( 28085938 )
2017
40
Quality of Life in Children and Youth with Obsessive-Compulsive Disorder. ( 28910139 )
2017
41
Investigating the role of anticipatory reward and habit strength in obsessive-compulsive disorder. ( 28065178 )
2017
42
Unpacking the role of self-reported compulsivity and impulsivity in obsessive-compulsive disorder. ( 28487007 )
2017
43
Enhanced error related negativity amplitude in medication-naA^ve, comorbidity-free obsessive compulsive disorder. ( 28941812 )
2017
44
C9orf72 hexanucleotide repeat expansions are not a common cause of obsessive-compulsive disorder. ( 28320191 )
2017
45
Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications. ( 28950396 )
2017
46
Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. ( 28903922 )
2017
47
Diagnostic validity of early-onset obsessive-compulsive disorder in the Danish Psychiatric Central Register: findings from a cohort sample. ( 28928194 )
2017
48
Epidemiology and comorbidity of obsessive-compulsive disorder in late adolescence: a cross-sectional study in senior high schools in Greece. ( 28504027 )
2017
49
The development and validation of static and adaptive screeners to measure the severity of panic disorder, social anxiety disorder, and obsessive compulsive disorder. ( 28370638 )
2017
50
Deep brain stimulation of the anterior limb of the internal capsule for treatment of therapy-refractory obsessive compulsive disorder (OCD): a case study highlighting neurocognitive and psychiatric changes. ( 28457185 )
2017

Variations for Obsessive-Compulsive Disorder

Copy number variations for Obsessive-Compulsive Disorder from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 77765 13 47471310 47471410 Deletion Obsessive-compulsive disorder
2 160222 22 11800000 24300000 Deletion Obsessive-compulsive disorder

Expression for Obsessive-Compulsive Disorder

Search GEO for disease gene expression data for Obsessive-Compulsive Disorder.

Pathways for Obsessive-Compulsive Disorder

Pathways related to Obsessive-Compulsive Disorder according to KEGG:

36
# Name Kegg Source Accession
1 Serotonergic synapse hsa04726
2 Dopaminergic synapse hsa04728
3 Glutamatergic synapse hsa04724

Pathways related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 COMT DLGAP3 MAOA SLC1A1 SLC6A3 SLC6A4
2
Show member pathways
12.6 COMT DRD2 DRD4 MAOA SLC1A1 SLC6A3
3 12.43 COMT HTR1A SLC1A1 TPH1 TPH2
4
Show member pathways
12.13 BDNF DRD2 HTR1A HTR1B
6 11.97 BDNF HTR1A HTR2A HTR3A MAOA SLC6A4
7
Show member pathways
11.85 BDNF DRD2 MAOA SLC6A3
8
Show member pathways
11.79 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
9 11.66 DRD2 HTR2A HTR2C
10 11.66 HTR1A HTR1B HTR2A HTR2C HTR3A MAOA
11
Show member pathways
11.3 MAOA SLC6A3 SLC6A4 TPH2
12
Show member pathways
11.04 COMT MAOA SLC6A3 SLC6A4
13
Show member pathways
10.95 COMT MAOA TPH1
14 10.87 HTR2A HTR2C
15
Show member pathways
10.73 COMT MAOA
16 10.72 HTR1A HTR1B HTR2A HTR2C HTR3A MAOA
17 10.69 COMT MAOA

GO Terms for Obsessive-Compulsive Disorder

Cellular components related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.8 COMT DLGAP3 DRD2 DRD4 HTR1A HTR1B
2 axon GO:0030424 9.55 COMT DRD2 HTR2A HTR3A SLC6A3
3 integral component of plasma membrane GO:0005887 9.32 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
4 integral component of membrane GO:0016021 10.1 COMT DRD2 DRD4 HTR1A HTR1B HTR2A

Biological processes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.93 HTR1B HTR2A HTR2C HTR3A SLC1A1
2 cellular calcium ion homeostasis GO:0006874 9.89 DRD4 HTR2A HTR2C
3 locomotory behavior GO:0007626 9.88 DRD2 HTR2C SLC6A3
4 circadian rhythm GO:0007623 9.88 SLC6A4 TPH1 TPH2
5 response to ethanol GO:0045471 9.88 DRD2 HTR1B HTR3A SLC6A3
6 memory GO:0007613 9.85 HTR2A OXT SLC6A4
7 positive regulation of synapse assembly GO:0051965 9.84 BDNF OXT SLITRK1
8 synapse assembly GO:0007416 9.84 BDNF DRD2 SLITRK1
9 positive regulation of fat cell differentiation GO:0045600 9.81 HTR2A HTR2C TPH1
10 social behavior GO:0035176 9.81 DRD4 OXT SLC6A4
11 feeding behavior GO:0007631 9.8 DRD2 HTR1B HTR2C
12 release of sequestered calcium ion into cytosol GO:0051209 9.78 DRD2 HTR2A HTR2C
13 behavioral fear response GO:0001662 9.74 DRD4 HTR1A HTR2C
14 response to iron ion GO:0010039 9.73 DRD2 SLC6A3
15 response to amphetamine GO:0001975 9.73 DRD2 DRD4 OXT
16 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD4
17 negative regulation of cAMP biosynthetic process GO:0030818 9.72 DRD4 HTR1B
18 positive regulation of kinase activity GO:0033674 9.72 DRD4 HTR2A
19 behavioral response to ethanol GO:0048149 9.72 DRD2 DRD4
20 bone remodeling GO:0046849 9.71 HTR1B TPH1
21 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A3 SLC6A4
22 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 DRD2 DRD4
23 ammonium transmembrane transport GO:0072488 9.71 SLC6A3 SLC6A4
24 prepulse inhibition GO:0060134 9.7 DRD2 SLC6A3
25 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 OXT
26 grooming behavior GO:0007625 9.7 DRD2 OXT
27 regulation of dopamine secretion GO:0014059 9.7 DRD2 HTR1B HTR2A
28 response to drug GO:0042493 9.7 COMT DRD2 HTR1B HTR2A HTR2C SLC6A3
29 G-protein coupled receptor internalization GO:0002031 9.69 DRD2 HTR1B
30 sleep GO:0030431 9.69 HTR2A OXT
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.69 DRD2 DRD4
32 behavioral response to cocaine GO:0048148 9.69 DRD2 DRD4 HTR2A
33 neurotransmitter catabolic process GO:0042135 9.68 COMT MAOA
34 catecholamine metabolic process GO:0006584 9.68 COMT MAOA
35 adenohypophysis development GO:0021984 9.68 DRD2 SLC6A3
36 monoamine transport GO:0015844 9.67 SLC6A3 SLC6A4
37 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.67 HTR1A HTR1B HTR2A
38 aromatic amino acid family metabolic process GO:0009072 9.66 TPH1 TPH2
39 drinking behavior GO:0042756 9.65 HTR1B OXT
40 dopamine uptake involved in synaptic transmission GO:0051583 9.65 SLC6A3 SLC6A4
41 sperm ejaculation GO:0042713 9.65 OXT SLC6A4
42 vasoconstriction GO:0042310 9.65 HTR1A HTR1B SLC6A4
43 regulation of hormone secretion GO:0046883 9.64 HTR1A HTR2A
44 indolalkylamine biosynthetic process GO:0046219 9.63 TPH1 TPH2
45 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.63 DRD2 HTR1B HTR2A
46 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.62 HTR2A HTR2C
47 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.61 HTR1A HTR1B
48 dopamine metabolic process GO:0042417 9.61 COMT DRD2 DRD4
49 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.6 DRD2 DRD4
50 serotonin biosynthetic process GO:0042427 9.59 TPH1 TPH2

Molecular functions related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.85 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
2 symporter activity GO:0015293 9.73 SLC1A1 SLC6A3 SLC6A4
3 neurotransmitter receptor activity GO:0030594 9.56 HTR1A HTR1B HTR2A HTR2C
4 neurotransmitter:sodium symporter activity GO:0005328 9.55 SLC6A3 SLC6A4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.52 DRD2 DRD4
6 monoamine transmembrane transporter activity GO:0008504 9.51 SLC6A3 SLC6A4
7 dopamine binding GO:0035240 9.5 DRD2 DRD4 SLC6A3
8 dopamine neurotransmitter receptor activity GO:0004952 9.49 DRD2 DRD4
9 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.48 TPH1 TPH2
10 dopamine:sodium symporter activity GO:0005330 9.46 SLC6A3 SLC6A4
11 G-protein coupled serotonin receptor activity GO:0004993 9.46 HTR1A HTR1B HTR2A HTR2C
12 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.43 HTR2A HTR2C
13 drug binding GO:0008144 9.43 DRD2 DRD4 HTR1B HTR2A HTR2C SLC6A3
14 tryptophan 5-monooxygenase activity GO:0004510 9.4 TPH1 TPH2
15 serotonin binding GO:0051378 9.02 HTR1A HTR1B HTR2A HTR2C HTR3A
16 G-protein coupled receptor activity GO:0004930 10.01 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C

Sources for Obsessive-Compulsive Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....